What is GeneDx Holdings's market cap?

GeneDx Holdings (WGS) has a market capitalization of $1.8B and trades on NASDAQ.

What is GeneDx Holdings's revenue and profitability?

GeneDx Holdings generated $442.7M in trailing twelve-month revenue with a net loss of $77.8M, representing a net margin of -17.6%. Gross margin stands at 69.6%, with free cash flow of -$17.2M. These figures are based on the Q1 2026 filing.

Who are GeneDx Holdings's competitors?

GeneDx Holdings's key competitors include Tempus, Natera, Personalis, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does GeneDx Holdings partner with?

GeneDx Holdings's notable partners include Illumina, Inc., Twist Biosciences Corporation, Agilent Technologies, and others.

What subsidiaries does GeneDx Holdings have?

GeneDx Holdings's subsidiaries include Fabric Genomics, Inc., GeneDx, LLC, Sema4 OpCo Inc..

Where is GeneDx Holdings headquartered?

GeneDx Holdings is headquartered in United States of America and employs approximately 1,000 people. It has been publicly traded since 2021.

GeneDx Holdings

WGS

GeneDx is a leader in genomics and precision medicine, specializing in exome and genome sequencing for rare and pediatric disorders.

Market cap

$1.8B-39.6%

Revenue$442.7M+34.1%

Net income-$77.8M-21.1%

Free cash flow-$17.2M+49.5%

EPS (diluted)-$2.68-10.7%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 4, 2026

Revenue$102.3MMiss by $10.2M EPS-$0.28Miss by $0.22

Read the full report

Next report

Aug 3, 2026 (In 4 days)

Revenue estimate$111.0M

EPS estimate-$0.19

Financials

Q1 2026

Income statement

See full

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

See full

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

See full

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation & ratios

Valuation

See full

Market cap$1.8B-39.6%

Enterprise value$1.8B-25.1%

P/S4.1×-2.6×

Profitability

See full

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

Returns & leverage

See full

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Competitors

By market cap

Natera, Inc.$37.0B+96.1%

Quest Diagnostics$25.6B+36.3%

Tempus AI, Inc.$7.7B-28.0%

GeneDx Holdings$1.8B-25.8%

Personalis, Inc.$1.3B+135%

Fulgent Genetics, Inc.$556.1M+1.4%

enGene Therapeutics Inc. $117.9M-36.6%

Cardio Diagnostics Holdings Inc.$4.8M-34.5%

By revenue growth

Tempus AI, Inc.+69.8%

Natera, Inc.+36.6%

GeneDx Holdings+34.1%

Quest Diagnostics+9.9%

Fulgent Genetics, Inc.+9.5%

Personalis, Inc.-24.7%

By net margin

Quest Diagnostics9.19%+0.2pp

Natera, Inc.-14.61%-3.2pp

GeneDx Holdings-17.58%+1.9pp

Tempus AI, Inc.-22.2%+66.1pp

Fulgent Genetics, Inc.-23.04%-9.1pp

Personalis, Inc.-148.11%-50.0pp

Profile

GeneDx is a leader in genomics and precision medicine, specializing in exome and genome sequencing for rare and pediatric disorders. The company leverages its proprietary GeneDx Infinity dataset, one of the world's largest rare disease genomic libraries, to provide clinicians with actionable diagnostic insights. Its core value proposition centers on transforming healthcare from reactive to proactive by delivering high-yield genetic diagnoses at the earliest moments of patient care.

Competitive position

GeneDx is a pioneer in clinical exome sequencing with a dominant position in the pediatric rare disease market. It maintains a competitive advantage through its massive proprietary dataset and FDA Breakthrough Device Designations for its core testing products.

GeographiesUnited States, International

Customer segmentsHealthcare Providers, Biopharmaceutical Companies, Health Systems, Payors

Business modelFee-for-service diagnostics, Data-as-a-Service (DaaS), SaaS (Software-as-a-Service)

SuppliersNext-generation sequencing equipment manufacturers, Laboratory reagent suppliers, Cloud computing infrastructure providers, Phlebotomy service providers

CustomersPatients, Medical specialists, Health insurance payors, Biopharma R&D departments

CountryUnited States of America

Listed2021

Employees1.0K

CEOKatherine A. Stueland

SectorHealthcare

IndustryMedical - Healthcare Information Services

Websitegenedx.com

FilingsSEC EDGAR

Ask your AI about GeneDx Holdings.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GeneDx Holdings's market cap?: GeneDx Holdings (WGS) has a market capitalization of $1.8B and trades on NASDAQ.
What is GeneDx Holdings's revenue and profitability?: GeneDx Holdings generated $442.7M in trailing twelve-month revenue with a net loss of $77.8M, representing a net margin of -17.6%. Gross margin stands at 69.6%, with free cash flow of -$17.2M. These figures are based on the Q1 2026 filing.
Who are GeneDx Holdings's competitors?: GeneDx Holdings's key competitors include Tempus, Natera, Personalis, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does GeneDx Holdings partner with?: GeneDx Holdings's notable partners include Illumina, Inc., Twist Biosciences Corporation, Agilent Technologies, and others.
What subsidiaries does GeneDx Holdings have?: GeneDx Holdings's subsidiaries include Fabric Genomics, Inc., GeneDx, LLC, Sema4 OpCo Inc..
Where is GeneDx Holdings headquartered?: GeneDx Holdings is headquartered in United States of America and employs approximately 1,000 people. It has been publicly traded since 2021.